Results 91 to 100 of about 45,546 (194)

Ameliorative Effect of Lycopene and Capsaicinoid Glucoside in Acute Myeloid Leukemia

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 11, November 2026.
Lycopene and capsaicinoid glucoside synergistically reduce leukemia cell proliferation, restore oxidative balance, and normalize hematological parameters in benzene‐induced rat models, demonstrating potent anti‐apoptotic and cytotoxic effects in vitro and in vivo.
Somia Shehzadi, Muhammad Abbas Shahid, Shaista Nazir, Murtaza Mansoor, Asmat Ullah, Fatima Iftikhar Shah, Zaid Talal Abdulqader Ali   +6 more
wiley   +1 more source

Protective effects of morin and propolis against cytarabine-induced neurotoxicity: a multi-biomarker approach

Open Life Sciences
Cytarabine (Cyt) is a cornerstone chemotherapeutic agent for acute myeloid leukemia (AML) and various hematological malignancies. This study sought to investigate the neuroprotective potential of morin and propolis against Cyt-induced neurotoxicity ...
Bağ Hakan, Yılmaz Seval, Çeribaşı Songül   +2 more
doaj   +1 more source

The Efferocytosis‐Driven Macrophage Polarization: A Concerto in the Tumor Immunosuppressive Microenvironment

MedComm, Volume 7, Issue 11, November 2026.
Efferocytosis is a key process for macrophages to clear apoptotic cells, which undergoes the “ Find Me” chemotaxis signal stage, the “eat me” phagocytosis recognition stage and the “digest me” digestion stage in turn. During the aforementioned three stages, various signaling molecules released by apoptotic cells can promote the phenotypic polarization ...
Qiuping Chen, Chunzhi Wu, Changquan Huang, Hang Zhou   +3 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Pronounced Reductions in Plasma Citrulline Indicate Severe Intestinal Mucosal Barrier Injury During Induction Therapy for Pediatric Acute Myeloid Leukemia

European Journal of Haematology, Volume 117, Issue 5, Page 1275-1284, November 2026.
ABSTRACT Objectives Pediatric acute myeloid leukemia (AML) chemotherapy regimens are frequently burdened by fever episodes, systemic inflammation and bloodstream infections (BSI). Mucosal barrier injury may contribute to these complications, but its role in childhood AML remains uninvestigated.
Carla Warley Kjær, Maria Ebbesen Sørum, Silvia De Pietri, Claus Moser, Malene Johanne Petersen, Marianne Hoffmann, Henrik Hasle, Sarah Weischendorff, Klaus Müller   +8 more
wiley   +1 more source

KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

European Journal of Haematology, Volume 117, Issue 5, Page 1318-1326, November 2026.
ABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Kensuke Takaoka, Sarah Mott, Ratdanai Yodsuwan, Sakditad Saowapa, Manasawee Tanariyakul, Chalothorn Wannaphut, Kittika Poonsombudlert   +6 more
wiley   +1 more source

Nucleolin Alterations and ROS Production Associate With Sensitivity of AML Cells to Venetoclax

The FASEB Journal, Volume 40, Issue 19, 15 October 2026.
Venetoclax‐induced Bcl‐2 inhibition corresponds with Mcl‐1 attenuation and decrease of Nucleolin (NCL) level and activity in sensitive cells. Simultaneously, distinct cell subpopulations with opposite mitochondrial (CellROX label, magenta) and cellular (H2DCFDA stain, green) ROS occur, and the H2DCFDA‐positive population shows markers of early ...
Kateřina Wolfová, Petra Otevřelová, Barbora Brodská   +2 more
wiley   +1 more source

Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant

Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
Matthew R. Schuelke, Julia Wang, Haley Newman, Evelyn Kurpiewski, Anne Reilly, Susan R. Rheingold, Gerald Wertheim, Moe Takeda, Daniel J. Zheng, Kaitlin Devine   +9 more
wiley   +1 more source

Control of Gemcitabine Activity With Blue and Red Light

Chemistry – A European Journal, Volume 32, Issue 38, 13 October 2026.
Treating cancer with chemotherapy is generally associated with many side effects, which can be addressed by selectively releasing the desired drugs with visible light. Sixteen new blue light‐activatable cytostatics were introduced, with the gemcitabine derivative exhibiting ideal properties.
Nils F. Kersten, Konstantin L. Stock, Marius Hyprath, Hannah Weisser, Timo Weinrich, Dieter Steinhilber, Alexander Heckel   +6 more
wiley   +1 more source

A Rare Case of Langerhans Cell Histiocytosis in the Hard Palate

Turkish Journal of Hematology, 2022
Memiş Hilmi Atay, Seda Gün
doaj   +1 more source